Versameb’s VMB-100 receives FDA clearance to enter clinic for stress urinary incontinence
Nov. 16, 2023
The FDA has cleared Versameb AG’s IND application for VMB-100, a potency-enhanced mRNA encoding human insulin-like growth factor-1 (IGF-1), for the treatment of stress urinary incontinence.
